Fractyl Health (GUTS) Return on Sales (2023 - 2024)
Fractyl Health's (GUTS) quarterly Return on Sales came in at 85.4% in Q4 2024, down 6664.0% YoY from 1.3% in Q1 2024, and down 45.09% on a QoQ basis from 58.86% in Q3 2024.
Fractyl Health (GUTS) Return on Sales (2023 - 2024) Analysis & Trends
Fractyl Health (GUTS) has 2 years of Return on Sales data on file, last reported at 85.4% in Q4 2024.
- Quarterly Return on Sales fell 6664.0% year-over-year to 85.4% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 23.29% (down 1911.0% YoY) and the FY2024 annual result came in at 22.5%, down 1034.0% from the prior year.
- Return on Sales slipped to 85.4% in Q4 2024, from 58.86% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 1.63% in Q2 2023 to a low of 85.4% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 0.00% |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | -0.05% |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 0.00% |
| 10 | Fractyl Health | 123.21 Mn | 123.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -85.40% |
| Sep 30, 2024 | -58.86% |
| Jun 30, 2024 | -19.19% |
| Mar 31, 2024 | -7.90% |
| Dec 31, 2023 | -18.76% |
| Sep 30, 2023 | -3.79% |
| Jun 30, 2023 | -1.63% |
| Mar 31, 2023 | -23.38% |